You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
微芯生物(688321.SH):西奧羅尼臨牀試驗申請獲受理
格隆匯 05-06 20:51

格隆匯5月6日丨微芯生物(688321.SH)公佈,公司近日收到國家藥監局簽發的IND(新藥臨牀試驗申請)《受理通知書》。

西奧羅尼是公司自主設計和研發的具有全球專利保護的新化學結構體,屬於多靶點多通路選擇性激酶抑制劑。屬於小分子抗腫瘤原創新藥,可選擇性抑制AuroraB、CSF1R和VEGFR/PDGFR/c-Kit等多個激酶靶點。

目前,西奧羅尼正在開展單藥治療小細胞肺癌和聯合紫杉醇治療卵巢癌的三期臨牀試驗以及治療肝癌、淋巴瘤、其他神經內分泌腫瘤等多個適應症的不同階段研究。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account